## Pfizer launches new medication for migraine treatment

## Synopsis

In a significant breakthrough for migraine sufferers in India, Pfizer has launched Rimegepant ODT, an innovative oral tablet that dissolves on the tongue. This medication provides rapid pain relief lasting up to 48 hours without the need for water, helping individuals reclaim lost days due to debilitating headaches.



Drug maker <u>Pfizer</u> on Monday said it has launched a new medication for migraine treatment.

The company has introduced

Rimegepant ODT in India for adults
with a previous insufficient response to
triptan, the usual drugs for treating
migraine.

The new medication delivers rapid and sustained pain relief lasting up to 48 hours post-treatment, while not associated with the risk of medication overuse headaches, Pfizer Ltd said in a statement.

Rimegepant will be available in a 75 mg orally disintegrating tablet (ODT) form, designed for convenient administration without the need for water, it added.

"We believe this treatment will help people with migraine manage pain more effectively and reclaim productive days sooner than with currently available options," Pfizer MD Meenakshi Nevatia stated.

Migraine poses a significant challenge in India, affecting around 213 million people annually, with an estimated 17.3 days of productivity loss observed per year.

## **News Source:**

https://economic times.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pfizer-launches-new-medication-for-migraine-treatment/articleshow/125381850.cms? from=mdr